Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first‐line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study

BACKGROUND The efficacy and safety of transarterial chemoembolization (TACE) plus lenvatinib in patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT) have not been evaluated. METHODS In this open‐label, single‐center, randomized trial (ClinicalTrials.gov identifier: NCT0...

Full description

Bibliographic Details

Published in:	Cancer 2021-10, Vol.127 (20), p.3782-3793
Main Authors:	Ding, Xiaoyan, Sun, Wei, Li, Wei, Shen, Yanjun, Guo, Xiaodi, Teng, Ying, Liu, Xiaomin, Zheng, Linlin, Li, Wendong, Chen, Jinglong
Format:	Article
Language:	eng
Subjects:	Blood clots Body weight Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - therapy Chemoembolization Chemoembolization, Therapeutic - adverse effects Clinical trials Hepatocellular carcinoma Humans lenvatinib Liver cancer Liver Neoplasms - pathology Medical prognosis Oncology Patients Phenylurea Compounds Portal vein Portal Vein - pathology portal vein thrombosis Prospective Studies Quinolines Radiation therapy Randomization Response rates Retrospective Studies Safety sorafenib Sorafenib - therapeutic use Statistical models Thrombosis Thrombosis - drug therapy Thrombosis - therapy Toxic hazards Toxicity transarterial chemoembolization Treatment Outcome Tumors
Online Access:	Request full text
Tags:	Add Tag No Tags, Be the first to tag this record!